Eyepoint Pharmaceuticals Stock Price on November 7, 2024
| EYPT Stock | USD 8.35 0.61 6.81% |
Below is the normalized historical share price chart for Eyepoint Pharmaceuticals extending back to January 27, 2005. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Eyepoint Pharmaceuticals stands at 8.35, as last reported on the 22nd of November, with the highest price reaching 9.07 and the lowest price hitting 8.25 during the day.
If you're considering investing in Eyepoint Stock, it is important to understand the factors that can impact its price. Eyepoint Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.002, which denotes the company had a -0.002% return per unit of risk over the last 3 months. Eyepoint Pharmaceuticals exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Eyepoint Pharmaceuticals' Downside Deviation of 4.3, mean deviation of 3.71, and Coefficient Of Variation of 18764.19 to check the risk estimate we provide.
At this time, Eyepoint Pharmaceuticals' Total Stockholder Equity is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 372.9 M in 2024, whereas Capital Stock is likely to drop slightly above 39 K in 2024. . At this time, Eyepoint Pharmaceuticals' Price Earnings To Growth Ratio is comparatively stable compared to the past year. Price To Operating Cash Flows Ratio is likely to gain to 490.63 in 2024, whereas Price Book Value Ratio is likely to drop 3.13 in 2024. Eyepoint Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 27th of January 2005 | 200 Day MA 13.6599 | 50 Day MA 9.7822 | Beta 1.517 |
Eyepoint |
Sharpe Ratio = -0.002
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EYPT |
Estimated Market Risk
| 5.82 actual daily | 51 51% of assets are less volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Eyepoint Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eyepoint Pharmaceuticals by adding Eyepoint Pharmaceuticals to a well-diversified portfolio.
Price Book 2.7942 | Enterprise Value Ebitda (11.49) | Price Sales 12.4668 | Shares Float 47.6 M | Wall Street Target Price 33.4546 |
Eyepoint Pharmaceuticals Main Headline on 7th of November 2024
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financia... by finance.yahoo.com
Announced positive interim data for DURAVYU 2.7mg in DME demonstrating meaningful, early and sustained visual acuity gains, strong anatomical control and a continued favorable safety profile BCVA and CST improvement of 8.9 letters and -68 microns, respectively, at 16-weeks Dosed first patient in Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU in wet AMD second LUCIA pivotal trial first patient dosing expected by end of 2024 161.0 million oversubscribed equity fina
Eyepoint Pharmaceuticals Valuation on November 7, 2024
It is possible to determine the worth of Eyepoint Pharmaceuticals on a given historical date. On November 7, 2024 Eyepoint was worth 12.41 at the beginning of the trading date compared to the closed value of 11.59. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Eyepoint Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Eyepoint Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Eyepoint Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Eyepoint Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 11.99 | 12.37 | 11.76 | 12.08 | 757,558 | |
11/07/2024 | 12.41 | 12.50 | 11.35 | 11.59 | 717,626 |
| 11.59 | 11.77 | 11.26 | 11.63 | 537,131 |
| Backtest Eyepoint Pharmaceuticals | | | Eyepoint Pharmaceuticals History | | | Eyepoint Pharmaceuticals Valuation | Previous | Next |
Eyepoint Pharmaceuticals Trading Date Momentum on November 7, 2024
| On November 08 2024 Eyepoint Pharmaceuticals was traded for 11.63 at the closing time. The top price for the day was 11.77 and the lowest listed price was 11.26 . The trading volume for the day was 537.1 K. The trading history from November 8, 2024 was a factor to the next trading day price appreciation. The overall trading delta against the next closing price was 0.35% . The overall trading delta against the current closing price is 20.88% . |
Eyepoint Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Eyepoint Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Eyepoint Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Eyepoint financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Eyepoint Pharmaceuticals Stock history
Eyepoint Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Eyepoint is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Eyepoint Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Eyepoint Pharmaceuticals stock prices may prove useful in developing a viable investing in Eyepoint Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 38.9 M | 40.8 M | |
| Net Loss | -92 M | -87.4 M |
Eyepoint Pharmaceuticals Quarterly Net Working Capital |
|
Eyepoint Pharmaceuticals Stock Technical Analysis
Eyepoint Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Eyepoint Pharmaceuticals Period Price Range
Low | November 22, 2024
| High |
0.00 | 0.00 |
Eyepoint Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Eyepoint Pharmaceuticals November 22, 2024 Market Strength
Market strength indicators help investors to evaluate how Eyepoint Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Eyepoint Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Eyepoint Pharmaceuticals stock market strength indicators, traders can identify Eyepoint Pharmaceuticals entry and exit signals to maximize returns
Eyepoint Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Eyepoint Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Eyepoint Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Eyepoint to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0127 | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.73) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0067 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.